• Read more about Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study.

Programmed death-ligand 1 (PD-L1) expression is correlated with objective response rates to PD-1 and PD-L1 immunotherapies.

• Read more about Personalized Therapeutics and Target Identification for Oral Diseases

Cancer networks were used to create predictive computational simulation models of head and neck squamous cell carcinoma (HNSCC) cell lines SCC4, SCC15, and SCC25.

• Read more about HBD3 Induced PD-L1 Expression in HNSCC

Human β-defensin 3 (HBD3) is present in high concentrations in the oral cavity of individuals with head and neck squamous cell carcinomas (HNSCC).

• Read more about Determination of Immune Evasion Phenotypes of HNSCC

The programmed death (PD-1/PD-L1) pathway is the focus of immunotherapeutic checkpoint inhibition for the control of head and neck squamous cell carcinoma (HNSCC). 

• Read more about Detection of PD-L1 expression on HNSCC cells

The Programmed Death (PD) pathway, involving receptor PD-1 on T-cells and ligand PD-L1 on tumor cells is an important immunotherapeutic checkpoint to inhibit in the control of head and neck squamous cell carcinoma (HNSCC).

• Read more about Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models

Interaction of the programmed death-1 (PD-1) co-receptor on T cells with the programmed death-ligand 1 (PD-L1) on tumor cells can lead to immunosuppression, a key event in the pathogenesis of many tumors.

• Read more about Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4

BACKGROUND:

Increasing evidence indicates that the interaction between the CXC chemokine receptor-4 (CXCR4) and its ligand CXCL12 is critical in the process of metastasis that accounts for more than 90% of cancer-related deaths.